Egros Fabrice 4
4 · Syndax Pharmaceuticals Inc · Filed Aug 20, 2021
Insider Transaction Report
Form 4
Egros Fabrice
Director
Transactions
- Exercise/Conversion
Common Stock
2021-08-18$7.88/sh+15,635$123,204→ 31,635 total - Sale
Common Stock
2021-08-18$15.75/sh−15,635$246,328→ 16,000 total - Exercise/Conversion
Stock Options (Right to buy)
2021-08-18−15,635→ 0 totalExercise: $7.88Exp: 2029-06-10→ Common Stock (0 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 77,682 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested.
- [F2]The sale prices ranged from $15.58 to $15.94.
- [F3]This option is fully vested.